Primidone
- Generic Name
- Primidone
- Brand Names
- Mysoline
- Drug Type
- Small Molecule
- Chemical Formula
- C12H14N2O2
- CAS Number
- 125-33-7
- Unique Ingredient Identifier
- 13AFD7670Q
Overview
Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954.
Background
Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954.
Indication
Primidone is commonly indicated for the management of grand mal, psychomotor, and focal epileptic seizures. In addition, it has also been studied and utilized as an effective management of essential tremor.
Associated Conditions
- Essential Tremor
- Generalized Tonic-Clonic Seizures
- Partial-Onset Seizures
- Temporal Lobe Epilepsy (TLE)
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.